Diabetes patients who took insulin glargine at 300 U/mL had an A1C of 7.25% at six months, while those who took the standard 100 U/mL formulation had an A1C of 7.28% during the same period, a study indicated. However, fewer patients who used the new formulation reported one or more confirmed or severe nocturnal hypoglycemia events than those in the standard treatment cohort, researchers reported in Diabetes Care.

Related Summaries